Understanding how epigenetic changes affect pancreatic cancer treatment resistance
Defining epigenetic signaling to reshape pancreatic tumor microenvironment
['FUNDING_R37'] · UNIVERSITY OF MICHIGAN AT ANN ARBOR · NIH-10857199
This study is looking at how changes in a specific gene called KMT2D affect the environment around pancreatic cancer tumors, with the hope of finding new ways to make these tumors easier to treat and improve immunotherapy for patients.
Quick facts
| Phase | ['FUNDING_R37'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MICHIGAN AT ANN ARBOR (nih funded) |
| Locations | 1 site (ANN ARBOR, UNITED STATES) |
| Trial ID | NIH-10857199 on ClinicalTrials.gov |
What this research studies
This research investigates the role of epigenetic signaling in pancreatic cancer, particularly focusing on how alterations in the KMT2D gene influence the tumor microenvironment. By using advanced 3D cell culture models and CRISPR technology, the study aims to uncover the mechanisms by which KMT2D loss leads to changes in immune cell behavior and tumor-associated fibroblasts. The ultimate goal is to develop new therapeutic strategies that can convert pancreatic tumors into a more treatable form, enhancing the effectiveness of immunotherapy for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic cancer, particularly those with specific genetic mutations related to KMT2D.
Not a fit: Patients with pancreatic cancer who do not have KMT2D mutations or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options and increased survival rates for patients with pancreatic cancer.
How similar studies have performed: Previous research has shown promising results in targeting epigenetic modifications to enhance cancer treatment, suggesting that this approach may be effective.
Where this research is happening
ANN ARBOR, UNITED STATES
- UNIVERSITY OF MICHIGAN AT ANN ARBOR — ANN ARBOR, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHI, JIAQI — UNIVERSITY OF MICHIGAN AT ANN ARBOR
- Study coordinator: SHI, JIAQI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.